Pharmaceuticals Synthetic Lethality: Q&A with Oren Gilad, CEO of Aprea Therapeutics Last updated: August 22, 2024 3:08 pm By bexib 0 Min Read Share SHARE Gilad discusses how this method could be used to treat a variety of cancers without exposing patients to the side effects of chemotherapy. You Might Also Like APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins New ways to determine drug value with health equity in mind Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer Share This Article Facebook Twitter Email Print Previous Article Bitcoin’s role as collateral in real estate development financing Next Article GLP-1 Therapy Significantly Increases Visceral Adipose Tissue Metabolic Activity in Patients with Obesity, Obstructive Sleep Apnea Leave a comment Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Stay ConnectedFacebookLikeTwitterFollowYoutubeSubscribeTelegramFollowLatest News Links 9/18/2024 | naked capitalism Economy ‘Act of terror’: Israel behind pager explosion that kills 11, injures thousands Economy Vermont’s 4T2D is expanding its American-made product line and training the next generation of factory workers. Manufacturing 2:00PM Water Cooler 9/18/2024 | naked capitalism Economy